Publications

PUBLICATIONS

Building the Foundation for Tomorrow's Medicines: The Science Behind Our Innovation

Our research has contributed to advancing the fields of nanomedicine, drug delivery, disease biology, and precision therapeutics. Explore a selection of peer-reviewed publications that have helped shape the scientific foundation of SMDG's proprietary technology platforms.

Crossing the Blood-Brain Barrier with Nanoligand Drug Carriers Self-assembled from a Phage Display Peptide

In a paper published in Nature Communications we show hierarchial forms of a brain-specific phage-derived peptide (herein as NanoLigand Carriers, NLCs) target cerebral endothelial cells through transferrin receptor and the receptor for advanced glycation-end products, cross the blood-brain-barrier and reach neurons and microglial cells.

Drug Delivery to the Brain: Self-Assembled Phage Mimetics for Crossing the Blood-Brain-Barrier

SMDG In a Nature Bioengineering Community, we discuss our pioneering platforms for efficient targeting of the brain and ferry nucleic acid medicines to neurons and microglia.

(Journal requires subscription)

Phage Mimetic Self-Assemblies Deliver Nucleic Acids to the Brain

The Blood-Brain Barrier (BBB) accounts for the failure of large number of promising neurotherapeutics including nucleic acid therapies. We show that phage mimetic self assemblies Nanocarrier Ligands (NLCs) carry nucleic acid therapeutics to the brain effectively and safely. The Nanomed Zone

A Rally for Brain Targeting: The Advent of a New Era

A Rally for Brain Targeting: The Advent of a New Era is an invited review by the founders of SMDG on brain targeting .

Journal of Therapeutic Delivery requires subscription

Some other papers by the founders

Moghimi SM, Simberg D, Papini E, Farhangrazi ZS. Complement activation by drug carriers and particulate pharmaceuticals: Principles, challenges and opportunities. Advanced Drug Delivery Reviews 2020, 157, 83-95.

Gifford G, Vu VP, Banda NK, Holers VM, Wang G, Groman EV, Backos D, Scheinman R, Moghimi SM, Simberg D. Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55. Journal of Controlled Release 2019, 302, 181-189.

Rahbarizadeh F, Ahmadvand D, Moghimi SM. CAR T-cell bioengineering: Single variable domain of heavy chain antibody targeted CARs. Advanced Drug Delivery Reviews 2019, 141, 41-46.

Moghimi SM. Cancer nanomedicine and the complement system activation paradigm: Anaphylaxis and tumour growth. Journal of Controlled Release 2014, 190, 556-562.

Moghimi SM, Farhangrazi ZS. Just so stories: The random acts of anti-cancer nanomedicine performance. Nanomedicine: Nanotechnology, Biology, and Medicine 2014, 10(8), 1661-1666.

Hall A, Wu L-P, Parhamifar L, Moghimi SM. Differential Modulation of Cellular Bioenergetics by Poly(L -lysine)s of Different Molecular Weights. Biomacromolecules 2015, 16(7), 2119-2126.

Moghimi SM, Hunter AC, Peer D. Platelet mimicry: The emperor's new clothes?. Nanomedicine: Nanotechnology, Biology, and Medicine 2016, 12(1), 245-248.